

# FILSPARI<sup>®</sup> (sparsentan)

## Edema and Congestive Heart Failure

### Summary

---

#### Prescribing Information

- FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression<sup>1</sup>
- In the PROTECT trial, the most common adverse reactions ( $\geq 5\%$ ) are hyperkalemia, hypotension (including orthostatic hypotension), peripheral edema, dizziness, anemia, and acute kidney injury<sup>1</sup>
- In the PROTECT trial, peripheral edema occurred in 33 (16%) patients taking FILSPARI compared to 29 (14%) patients taking irbesartan<sup>1</sup>

#### Background

- Sparsentan is a novel, first-in-class, and the only single molecule antagonist of the ET<sub>A</sub> and AT<sub>1</sub> receptors<sup>2-4</sup>

#### Study Data

- In the phase 3 PROTECT study, change in edema from no edema at baseline to severe edema occurred in 2 (1%) irbesartan-treated patients and from no edema at baseline to moderate edema in 2 (1%) sparsentan-treated patients<sup>5</sup>
- In the phase 2 DUET study, higher incidence of peripheral edema was reported in patients taking sparsentan (12.3%) compared to those on irbesartan (2.8%) during the 8-week double-blind period<sup>4</sup>
- An analysis of DUET OLE data found that peripheral edema was the second most common TEAE reported across 240 weeks of sparsentan treatment (11.2 total study duration cases per 100 patient-years)<sup>6</sup>
- In the phase 3 DUPLEX study, no clinically meaningful concerns regarding edema were reported<sup>7</sup>
- In the phase 2 EPIK study of pediatric patients (N=34), 2 patients experienced peripheral edema and 1 patient reported edema<sup>8</sup>
- In the phase 2 SPARTACUS study of sparsentan in combination with SGLT2 inhibitors, among enrolled patients (N=20), edema and peripheral edema were each reported in 2 (10%) patients<sup>9</sup>
- No studies have been specifically conducted to evaluate any association between sparsentan and CHF. To date, no cases of CHF were observed in the DUET, DUPLEX, or PROTECT studies<sup>10</sup>

## Prescribing Information

In the PROTECT trial, the most common adverse reactions ( $\geq 5\%$ ) are hyperkalemia, hypotension (including orthostatic hypotension), peripheral edema, dizziness, anemia, and acute kidney injury.<sup>1</sup>

In the PROTECT trial, peripheral edema occurred in 33 (16%) patients taking FILSPARI compared to 29 (14%) patients taking irbesartan.<sup>1</sup>

In patients taking FILSPARI, monitor blood pressure, serum potassium, edema, and kidney function regularly when used concomitantly with moderate CYP3A inhibitors.<sup>1</sup>

For more information, please refer to the Prescribing Information, including Boxed Warning.

## Background

Sparsentan is a novel, first-in-class, and the only single molecule antagonist of the  $ET_A$  and  $AT_1$  receptors.<sup>2-4</sup> Preclinical studies in rodent models of chronic kidney disease have shown that blockade of both  $ET_A$  and  $AT_1$  pathways reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation.<sup>11-13</sup>

### The PROTECT Study

The PROTECT study ([NCT03762850](#)) is a phase 3, global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating long-term antiproteinuric and nephroprotective efficacy and safety of 400 mg of sparsentan in patients with IgA nephropathy compared to 300 mg of irbesartan.<sup>14</sup> The study includes 404 patients ages 18 years and older with biopsy proven IgA nephropathy who experience persistent proteinuria despite available ACEi or ARB therapy. Patients with urine protein  $\geq 1$  g/day at screening,  $eGFR \geq 30$  mL/min/1.73 m<sup>2</sup>, SBP  $\leq 150$  mm Hg, and DBP  $\leq 100$  mm Hg were eligible.<sup>15</sup> The PROTECT study protocol provides for an unblinded interim analysis of at least 280 patients to be performed after 36 weeks of treatment to evaluate the primary efficacy endpoint, defined as change in proteinuria (UPCR) at Week 36 from baseline. Secondary efficacy endpoints include the rate of change in eGFR following the initiation of randomized treatment over 58-week and 110-week periods, as well as rate of change in eGFR over 52-week and 104-week periods following the first 6 weeks of randomized treatment.<sup>15,16</sup> The PROTECT study also examines change from baseline in UACR based on a 24-hour urine sample at Week 36, and prespecified exploratory endpoints of complete (UPE  $< 0.3$  g/day) and partial (UPE  $< 1.0$  g/day) proteinuria remission at least once at any time during the double-blind period. In addition, this study evaluates the proportion of patients in each group reaching a confirmed 40% reduction in eGFR from baseline, KF, or all-cause mortality. KF is defined as initiation of KRT or sustained eGFR value of  $< 15$  mL/min/1.73 m<sup>2</sup>.<sup>17</sup> Reduction in proteinuria and decline in rate of eGFR are largely accepted as surrogate markers of treatment effect in studies of KF.<sup>17,18</sup>

### The DUET Study

The DUET study ([NCT01613118](#)) is a phase 2, randomized, multicenter, double-blind, active-control trial examining the safety and efficacy of sparsentan compared to irbesartan in patients with biopsy-proven FSGS. Patients were randomized to 1 of 3 doses (200, 400, or 800 mg/day) of sparsentan or irbesartan (300 mg/day) and maintained through an 8-week double-blind phase. The primary endpoint was defined as reduction in UPCR after 8 weeks of treatment. The proportion of patients who achieved partial FSGS remission was evaluated as a secondary endpoint. Following the double-blind phase, patients had the option to continue into a 144-week OLE of treatment with sparsentan.<sup>4</sup>

## The DUPLEX Study

The DUPLEX study ([NCT03493685](#)) is a global, randomized, multicenter, double-blind, active-controlled, phase 3 trial examining the safety and efficacy of sparsentan as compared to irbesartan in patients aged 8 to 75 years with biopsy-proven FSGS. Patients with UPCR  $\geq 1.5$  g/g at screening, eGFR  $\geq 30$  mL/min/1.73 m<sup>2</sup>, and mean seated BP  $\geq 100/60$  mm Hg (patients  $\geq 18$  years) or above the 5<sup>th</sup> percentile for sex and height (<18 years) were eligible. After a 2-week washout period, 371 patients were randomized to receive either sparsentan or irbesartan, and subsequently dose titrated over 2 weeks to the maximum dose of either 800 mg/day sparsentan or 300 mg/day irbesartan, as tolerated.<sup>7,19</sup> Patients remained on maintenance doses of sparsentan or irbesartan during a 108-week double blind phase. Standard-of-care treatment, including RAASi, was resumed in Weeks 108-112. The primary efficacy endpoint was eGFR slope over 108 weeks of treatment, defined as eGFR total slope from Day 1 to Week 108 of treatment and eGFR chronic slope from Week 6 to Week 108 (following the initial acute effect of randomized treatment). The key secondary endpoint was percent change in eGFR from baseline to 4 weeks post-cessation of randomized treatment at Week 112.<sup>7</sup> An additional interim endpoint was the proportion of patients achieving partial remission of proteinuria, defined as UPCR  $\leq 1.5$  g/g and a >40% reduction (FPRE) at Week 36. Proportion of patients achieving complete remission of proteinuria (UPCR <0.3 g/g) at any time in the double-blind period was also examined. Safety was assessed by double-blind monitoring of adverse events and safety endpoints.<sup>7,19</sup>

## Study Data

### The PROTECT Study

In the PROTECT study, protocol allowances were made for the management of patients with worsening edema. Patients received half the target dose for the first 2 weeks after randomization. Dose tolerance was evaluated in a blinded manner at the Week 2 visit and was defined as systolic blood pressure >100 mm Hg and diastolic blood pressure >60 mm Hg after 2 weeks, and no AEs (eg, worsening edema) or laboratory findings interfering with the patient's continuation on study medication. Patients who did not tolerate the initial dose for any reason could discontinue the study medication and could re-start or reduce the study medication at the investigator's discretion. Potassium-sparing diuretics were not to be coadministered with sparsentan in the PROTECT study.<sup>15</sup>

#### 2-Year Safety Analysis

Over 2 years of treatment, peripheral edema was reported in 33 (16%) sparsentan patients and 29 (14%) irbesartan patients.<sup>1</sup> Change from no edema at baseline to severe edema occurred in 0 sparsentan-treated patients and 2 irbesartan-treated patients. Change to moderate edema occurred in 2 patients taking sparsentan and none taking irbesartan. Diuretic use initiated on or after beginning study drug was reported in 49 (24%) sparsentan patients and 54 (27%) irbesartan patients. The most frequent were thiazides, utilized by 35 (17%) and 42 (21%) sparsentan and irbesartan patients, respectively. No patients discontinued treatment due to edema and no serious AEs of fluid retention were reported. Dual antagonism of ET<sub>A</sub> and AT<sub>1</sub> receptors may decrease the risk of fluid retention.<sup>5,20</sup>

#### Subgroup Analyses

The PROTECT study included additional analyses in which patients were divided into groups per baseline proteinuria, <1.0 g/g or  $\geq 1.0$  g/g. In the <1.0 g/g group (n=145), peripheral edema was

Summary	PI	Background	Study Data	Abbreviations	References
---------	----	------------	------------	---------------	------------

reported in 9/77 (12%) patients taking sparsentan and 7/68 (10%) patients taking irbesartan. Among patients with baseline UPCR  $\geq 1.0$  g/g (n=259), peripheral edema occurred in 22/125 (18%) sparsentan-treated patients and 17/134 (13%) irbesartan-treated patients.<sup>21</sup>

### PROTECT OLE

In the PROTECT OLE, among patients receiving concomitant sparsentan and SGLT2 inhibitor treatment (N=61), peripheral edema was reported as a TEAE in 3 (5%) patients; no cases were considered serious.<sup>22</sup>

### The DUET Study

During the 8-week double-blind period, higher incidence of peripheral edema was reported in patients taking sparsentan compared to those on irbesartan. Across all 3 sparsentan dose cohorts, 12.3% (n=9) of patients experienced edema vs 2.8% (n=1) of patients taking irbesartan.<sup>4</sup>

There were no significant changes in severity of edema during the double-blind period and no meaningful between-group differences in use of diuretic treatment. However, loop diuretics were used more frequently in sparsentan-treated patients than in irbesartan-treated patients. The proportion of patients in the sparsentan group with mild to moderate edema remained stable, whereas the proportion with severe edema rose from 2% to 5%. This occurred in parallel with an increase in the use of loop diuretics. At baseline, patients displayed varying degrees of edema, and there were no significant changes in body weight or N-terminal pro-B-type natriuretic peptide levels from baseline in sparsentan-treated patients. There were no study withdrawals or severe TEAEs related to edema.<sup>4</sup>

Analysis of long-term efficacy and safety data in the DUET study found that headache and peripheral edema were the 2 most common TEAEs across 240 weeks of sparsentan treatment, with incidence of 11.7 and 11.2 total study duration cases per 100 patient-years, respectively (**Table 1**).<sup>6</sup>

**Table 1. Most Common TEAEs by Year and Cases Per 100 Patient-Years for Total Study Duration in the DUET OLE Study**

	n (%) Within Each Year					Total Study Duration Cases Per 100 Patient-Years, Cases/100 Patient Years
	Year 0 to <1 n=108	Year 1 to <2 n=87	Year 2 to <3 n=72	Year 3 to <4 n=60	Year 4 to <5 n=54	
Headache	25 (23.1)	5 (5.7)	1 (1.4)	4 (6.7)	2 (3.7)	11.7
Edema peripheral	15 (13.9)	10 (11.5)	3 (4.2)	2 (3.3)	2 (3.7)	11.2
Upper respiratory tract infection	9 (8.3)	5 (5.7)	6 (8.3)	5 (8.3)	2 (3.7)	10.6
Hyperkalemia	7 (6.5)	9 (10.3)	3 (4.2)	6 (10.0)	6 (11.1)	10.4
Hypotension	17 (15.7)	6 (6.9)	3 (4.2)	2 (3.3)	1 (1.9)	9.3
Nausea	17 (15.7)	3 (3.4)	2 (2.8)	4 (6.7)	1 (1.9)	8.5
Hypertension	6 (5.6)	7 (8.0)	2 (2.8)	3 (5.0)	6 (11.1)	7.6
Vomiting	12 (11.1)	2 (2.3)	5 (6.9)	2 (3.3)	1 (1.9)	7.6
Diarrhea	14 (13.0)	3 (3.4)	3 (4.2)	1 (1.7)	4 (7.4)	7.1
Dizziness	14 (13.0)	3 (3.4)	1 (1.4)	2 (3.3)	0	6.3
Blood creatinine increased	11 (10.2)	1 (1.1)	4 (5.6)	0	1 (1.9)	5.5
Blood creatine phosphokinase increased	8 (7.4)	2 (2.3)	0	3 (5.0)	2 (3.7)	4.9
Anemia	11 (10.2)	1 (1.1)	0	2 (3.3)	1 (1.9)	4.1

### The DUPLEX Study

At baseline, 9 (4.9%) sparsentan patients and 6 (3.2%) irbesartan patients presented with moderate or severe edema. Over 108 weeks of treatment, peripheral edema was the second most common TEAE in  $\geq 10\%$  of patients, occurring in 36 (19.6%) patients in the sparsentan group and 41 (21.9%) patients taking irbesartan. There were no clinically meaningful concerns regarding edema among patients taking sparsentan.<sup>7</sup>

## Additional Clinical Trials

### *The EPIIK Study*

In the EPIIK study of sparsentan treatment in pediatric patients with rare proteinuric kidney diseases (N=34), 2 patients experienced peripheral edema and 1 patient reported edema.<sup>8</sup>

### *The SPARTACUS Study*

The ongoing SPARTACUS study assesses safety and efficacy of sparsentan in combination with stable SGLT2 inhibitors. In an interim analysis of enrolled patients (N=20), edema and peripheral edema were each reported in 2 (10%) patients.<sup>9</sup>

## Congestive Heart Failure

No studies have been specifically conducted to evaluate any association between sparsentan and CHF. To date, no cases of CHF have been observed in the DUET, DUPLEX, or PROTECT studies.<sup>10</sup>

## Abbreviations

---

ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; AT<sub>1</sub>, angiotensin II type 1; CHF, congestive heart failure; CYP, cytochrome P; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ET<sub>A</sub>, endothelin-1 type A; FDA, US Food and Drug Administration; FPRE, FSGS partial remission endpoint; FSGS, focal segmental glomerulosclerosis; IgA, immunoglobulin A; ITT, intention-to-treat; KF, kidney failure; KRT, kidney replacement therapy; OLE, open-label extension; RAASi, renin-angiotensin-aldosterone system inhibitor; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter-2; TEAE, treatment-emergent adverse event; UACR, urine albumin-to-creatinine ration; UPCR, urine protein-to-creatinine ratio; UPE, urinary protein excretion.

## References

---

1. FILSPARI. Prescribing information. Traverre Therapeutics Inc; September 2024.
2. Komers R, Gipson DS, Nelson P, et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: Randomized, controlled trial design (DUET). *Kidney Int Rep*. 2017;2(4):654-664. doi:10.1016/j.ekir.2017.02.019
3. Raczynska A, Pawlowicz-Szlarska E, Nowicki M. Sparsentan—a dual antagonist—literature review on endothelin and endothelin antagonists. *Nephrol Dial Pol*. 2021;25:77-82.
4. Trachtman H, Nelson P, Adler S, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. *J Am Soc Nephrol*. 2018;29(11):2745-2754. doi:10.1681/ASN.2018010091
5. Rovin B, Barratt J, Heerspink HJ, et al. Efficacy and safety of sparsentan vs irbesartan in patients with IgA nephropathy: 2-year results from PROTECT, a phase 3 randomized active-controlled clinical trial. *Lancet*. 2023;402(10417):2077-2090. doi:10.1016/S0140-6736(23)02302-4

6. Srivastava T, Tesar V, Campbell KN, et al. Long-term efficacy and safety of sparsentan in FSGS: 240-week analysis of the DUET open-label extension (OLE). Abstract presented at: ASN Kidney Week; November 3-6 2022; Orlando, FL.
7. Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. *N Engl J Med*. 2023;389(26):2436-2445. doi:10.1056/NEJMoa2308550
8. Trachtman H, Coppo R, Ahmed NAM, et al. Sparsentan in pediatric patients with rare proteinuric kidney disease: Preliminary findings from the EPIIK study. Poster presented at: ASN Kidney Week; October 23-27, 2024; San Diego, CA.
9. Ayoub I, Tang S, Kooienga L, et al. Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors in adults with IgA nephropathy in the ongoing phase 2 SPARTACUS trial. Poster presented at: ASN Kidney Week; October 24-27, 2024; San Diego, CA.
10. Data on file. Traverse Therapeutics Inc; 2024.
11. Nagasawa H, Suzuki H, Jenkinson C, et al. Sparsentan, the dual endothelin angiotensin receptor antagonist (DEARA), attenuates albuminuria and protects from the development of renal injury to a greater extent than losartan in the gddY mouse model of IgA nephropathy: A 16-week study. Mini oral presented at: ERA-EDTA Congress; May 19-22, 2022; Paris, France.
12. Nagasawa H, Suzuki H, Jenkinson C, et al. The dual endothelin type A receptor (ET<sub>A</sub>R) and angiotensin II type 1 receptor (AT<sub>1</sub>R) antagonist, sparsentan, protects against the development of albuminuria and glomerulosclerosis in the gddY mouse model of IgA nephropathy. Poster presented at: ERA-EDTA Virtual Congress; June 6-9, 2020; Virtual Meeting.
13. Bedard P, Jenkinson C, Komers R. Sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis (FSGS). Abstract presented at: ERA-EDTA Congress; May 19-22, 2022; Paris, France.
14. Barratt J, Rovin B, Wong MG, et al. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. *Kidney Int Rep*. 2023:1-14. doi:10.1016/j.ekir.2023.02.1086
15. Barratt J, Rovin B, Diva U, Mercer A, Komers R, PROTECT Study Design Group. Supplementary material: Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). *Kidney Int Rep*. 2019;4(11):1633-1637. doi:10.1016/j.ekir.2019.08.007
16. Wong M, Barratt J, Komers R, Mercer A, Rosenberg N. Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT). Mini Oral presented at: ERA-EDTA Congress; May 19-22, 2022; Paris, France.
17. Heerspink HJ, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised double-blind active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X
18. Thompson A, Carroll K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. *Clin J Am Soc Nephrol*. 2019;14(3):469-481. doi:10.2215/CJN.08600718

19. Komers R, Diva U, Inrig JK, Loewen A, Trachtman H, Rote WE. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. *Kidney Int Rep.* 2020;5(4):494-502. doi:10.1016/j.ekir.2019.12.017
20. Hendry BM, Kohan DE, Geletka R, Jenkinson C, Chen S-C, Bedard PW. Sparsentan receptor occupancy, modeling, clinical actions, and safety. presented at: WCN; April 13 - 16 2024; Buenos Aires, Argentina.
21. Kooienga L, Trimarchi H, Floege J, Preciado P, Murphy E, Radhakrishnan J. PROTECT subgroup analysis: Sparsentan provides clinical benefits vs irbesartan in patients with IgA nephropathy with proteinuria above and below 1 g/g. Oral presentation presented at: ASN Kidney Week; October 23-27, 2024; San Diego, CA.
22. Kooienga L, Malecki R, Preciado P, Nandola H, Mercer A. Concomitant sparsentan (SPAR) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with IgA nephropathy (IgAN) in the PROTECT open-label extension (OLE). Poster presented at: ASN Kidney Week; October 23-27, 2024; San Diego, CA.